Incorporates HPV Self-Collection Recommendations

Extended HPV Genotyping Support.

Expanded post-colposcopy guidance and updated ASC-US cotest recommendations.

Dual Stain Management: We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making. SmartUI Enhancement: Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points.

Dual Stain Management: We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making. SmartUI Enhancement: Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points.

Dual Stain Management: We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making. SmartUI Enhancement: Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points.

Dual Stain Management: We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making. SmartUI Enhancement: Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points.

Recommendation updates based on new erratum publication.

Minor improvements to management recommendations and typographical errors

New Clinical Situations tree to aide in navigation. Expanded app to include Screening Guidelines.

New 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors provide new recommendations.

New 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors provide new recommendations.

New 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors provide new recommendations.